Stay updated on ACP-196 and Pembrolizumab in Pancreatic Cancer Clinical Trial
Sign up to get notified when there's something new on the ACP-196 and Pembrolizumab in Pancreatic Cancer Clinical Trial page.

Latest updates to the ACP-196 and Pembrolizumab in Pancreatic Cancer Clinical Trial page
- Check3 days agoNo Change Detected
- Check10 days agoChange DetectedThe site revision label has been updated to v3.5.0, replacing the previous v3.4.3.SummaryDifference0.1%

- Check18 days agoChange DetectedRevision: v3.4.3 updated from v3.4.2.SummaryDifference0.1%

- Check25 days agoNo Change Detected
- Check47 days agoChange DetectedAdded Revision: v3.4.2. Removed the funding-lapse notice and the older Revision: v3.4.1.SummaryDifference0.5%

- Check54 days agoChange DetectedA government funding lapse notice was added at the top of the page, warning that information may not be up to date and that the NIH Clinical Center is open, and the site revision label was updated from v3.4.0 to v3.4.1.SummaryDifference0.5%

- Check61 days agoChange DetectedAdded Show glossary option and a new 'Last Update Submitted that Met QC Criteria' label. Updated capitalization of 'No FEAR Act Data' and the page revision to v3.4.0 (from v3.3.4).SummaryDifference0.3%

- Check75 days agoChange DetectedThe page now displays Revision: v3.3.4, replacing the prior Revision: v3.3.3.SummaryDifference0.1%

Stay in the know with updates to ACP-196 and Pembrolizumab in Pancreatic Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the ACP-196 and Pembrolizumab in Pancreatic Cancer Clinical Trial page.